An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT
Latest Information Update: 25 Nov 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 21 Nov 2021 Status changed from active, no longer recruiting to completed.
- 24 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 24 Apr 2018 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.